Medicare Enrolled
Dr. Horace Tang, M.D.
Hematology & Oncology · Brooklyn, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tang
Dr. Horace Tang is a hematology & oncology specialist in Brooklyn, NY, with 16 years of NPI registration. Based on federal Medicare data, Dr. Tang performed 2,621 Medicare services across 1,293 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tang received a total of $17,598 from 61 pharmaceutical and/or device companies across 548 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 28% volume in NY
$17,598 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,621
Medicare services
Top 28% in NY for hematology & oncology
1,293
Unique beneficiaries
$52
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~164 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
654 | $8 | $47 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
646 | $101 | $755 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
555 | $8 | $15 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
183 | $72 | $234 |
| SARS-CoV-2 immunoassay test A laboratory test using immunoassay techniques to detect the presence of severe acute respiratory syndrome coronavirus. |
98 | $35 | $60 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
87 | $95 | $620 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
67 | $64 | $516 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
65 | $97 | $519 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
62 | $139 | $1,029 |
| New patient office visit, complex (60-74 min) | 39 | $148 | $984 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
37 | $104 | $864 |
| Influenza virus detection test A laboratory test that uses an immunoassay technique to detect the presence of the influenza virus through direct visual observation. |
26 | $16 | $58 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $133 | $1,100 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
19 | $152 | $1,113 |
| Caregiver health risk assessment A procedure involving the administration and interpretation of a health risk assessment specifically focused on caregivers. |
18 | $2 | $50 |
| Behavioral health care management, 20+ minutes This service involves clinical staff time directed by a healthcare professional to manage behavioral health conditions. It requires at least 20 minutes of dedicated clinical staff time. |
15 | $37 | $75 |
| Adm sarscv2 bvl 50mcg/.5ml a | 12 | $47 | $60 |
| SARS-CoV-2 vaccine, 50 mcg/0.5 mL Administration of a SARS-CoV-2 vaccine containing 50 micrograms of antigen in a 0.5 milliliter dose. |
12 | $0 | $10 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$17,598
Total received (2018-2024)
Avg $2,514/year across 7 years
Top 19% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
61
Companies
548
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,423 (64.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,106 (29.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,069 (6.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,216
2023
$2,845
2022
$2,055
2021
$930
2020
$3,499
2019
$2,043
2018
$4,010
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$1,426
ABBVIE INC.
$178
PFIZER INC.
$103
Daiichi Sankyo Inc.
$64
Incyte Corporation
$52
Gilead Sciences, Inc.
$49
Regeneron Healthcare Solutions, Inc.
$33
Novartis Pharmaceuticals Corporation
$32
Sumitomo Pharma America, Inc.
$32
Celgene Corporation
$31
E.R. Squibb & Sons, L.L.C.
$29
Bayer Healthcare Pharmaceuticals Inc.
$23
Eisai Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$18
GlaxoSmithKline, LLC.
$17
EMD Serono, Inc.
$17
Exelixis Inc.
$16
Janssen Biotech, Inc.
$16
PharmaEssentia USA Corporation
$16
Astellas Pharma US Inc
$16
Mirati Therapeutics, Inc.
$15
Blueprint Medicines Corporation
$15
Top 3 companies account for 77.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$5,335
Daiichi Sankyo Inc.
$1,126
E.R. Squibb & Sons, L.L.C.
$851
Incyte Corporation
$847
Astellas Pharma US Inc
$842
Novartis Pharmaceuticals Corporation
$725
Janssen Biotech, Inc.
$664
Exelixis Inc.
$546
PFIZER INC.
$540
Takeda Pharmaceuticals U.S.A., Inc.
$521
Merck Sharp & Dohme Corporation
$467
Gilead Sciences, Inc.
$444
Genentech USA, Inc.
$418
Lilly USA, LLC
$346
Celgene Corporation
$331
TESARO, Inc.
$278
Eisai Inc.
$253
Amgen Inc.
$251
Foundation Medicine, Inc.
$237
Covis Pharma GmBH
$200
ABBVIE INC.
$178
Rigel Pharmaceuticals, Inc.
$175
Seagen Inc.
$163
Regeneron Healthcare Solutions, Inc.
$140
AVEO Pharmaceuticals, Inc.
$132
Novocure Inc.
$122
Pharmacosmos Therapeutics Inc.
$115
Pharmacyclics LLC, An AbbVie Company
$105
Merck Sharp & Dohme LLC
$93
Myriad Genetic Laboratories, Inc.
$88
Henry Schein, Inc.
$83
GlaxoSmithKline, LLC.
$75
EISAI INC.
$70
Mirati Therapeutics, Inc.
$60
Clovis Oncology, Inc.
$53
Bayer Healthcare Pharmaceuticals Inc.
$50
Sumitomo Pharma America, Inc.
$47
EMD Serono, Inc.
$45
PharmaEssentia USA Corporation
$45
Myovant Sciences Inc.
$45
Janssen Pharmaceuticals, Inc
$45
Puma Biotechnology, Inc.
$44
GENZYME CORPORATION
$43
Kite Pharma, Inc.
$40
Bayer HealthCare Pharmaceuticals Inc.
$29
Blueprint Medicines Corporation
$28
TerSera Therapeutics LLC
$25
ADC Therapeutics America, Inc.
$23
SOBI, INC
$23
Sobi, Inc
$18
Amarin Pharma Inc.
$18
Helsinn Therapeutics (U.S.), Inc.
$18
BeiGene USA, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$17
ARRAY BIOPHARMA INC
$15
PUMA BIOTECHNOLOGY, INC.
$15
EUSA Pharma (US) LLC
$15
Kyowa Kirin, Inc.
$15
JAZZ PHARMACEUTICALS INC.
$15
Taiho Oncology, Inc.
$15
Veracyte, Inc.
$10
Top 3 companies account for 41.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Alecensa · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABOMETYX · CALQUENCE · CERDELGA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ENHERTU · EPKINLY · ERLEADA · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · GAZYVA · Gazyva · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MAVYRET · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · Monoferric · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OPDIVO · OPDUALAG · ORGOVYX · Oncology · PADCEV · PIQRAY · POTELIGEO · PROMACTA · Padcev · Perjeta · Pomalyst · Prolia · REBLOZYL · RETEVMO · Rezlidhia · Rubraca · SCEMBLIX · SUTENT · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Tavalisse · Tibsovo · Trodelvy · VERZENIO · VOTRIENT · Vanflyta · Vascepa · Venclexta · XALKORI · XARELTO · XTANDI · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYKADIA · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (65%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
727
Per 100K population
27.5
County median income
$78,548
Nearest hospital
MAIMONIDES MEDICAL CENTER
1.2 mi
1.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tang is a clinical cardiology specialist, with above-average Medicare volume (top 28% in NY), with low-engagement industry engagement in the top 19% of NY peers, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tang experienced with complete blood count (cbc) with differential?
Based on Medicare claims data, Dr. Tang performed 654 complete blood count (cbc) with differential services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tang receive payments from pharmaceutical companies?
Yes. Dr. Tang received a total of $17,598 from 61 companies across 548 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tang's costs compare to other hematology & oncology specialists in Brooklyn?
Dr. Tang's average Medicare payment per service is $52. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Brooklyn
Browse hematology & oncology specialists in Brooklyn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology